PE02222009A1 - Compounds [6,6] and [6,7] -biciclicos as agonists coupled receptor protein g GPR119 - Google Patents

Compounds [6,6] and [6,7] -biciclicos as agonists coupled receptor protein g GPR119

Info

Publication number
PE02222009A1
PE02222009A1 PE0007772008A PE0007772008A PE02222009A1 PE 02222009 A1 PE02222009 A1 PE 02222009A1 PE 0007772008 A PE0007772008 A PE 0007772008A PE 0007772008 A PE0007772008 A PE 0007772008A PE 02222009 A1 PE02222009 A1 PE 02222009A1
Authority
PE
Peru
Prior art keywords
aryl
compounds
oxazin
phenylamino
methylsulfonyl
Prior art date
Application number
PE0007772008A
Other languages
Spanish (es)
Inventor
John M Fevig
Dean A Wacker
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US91594407P priority Critical
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of PE02222009A1 publication Critical patent/PE02222009A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Abstract

REFERIDA A UN COMPUESTO HETEROCICLICO DE FORMULA (I), DONDE A, BYD SON CR4a ON; Referring to a heterocyclic compound of formula (I), where A, b and d are CR4A ON; E ES CH2, OO NH; E is CH2, NH OO; G ES CH ON; G is CH ON; Y ES NR3, OOS; Y is NR 3, OOS; Z ESTA AUSENTE O ES =O; Z is absent or is = O; n1 ES 1 O 2; n1 is 1 or 2; n2 Y n3 SON UN ENTERO DE 0 A 2; N2 and N3 an integer of 0 to 2; R1 ES ARILO O HETEROARILO OPCIONALMENTE SUSTITUIDO CON R4; R1 is aryl or heteroaryl optionally substituted with R4; R2 ES ARILO, C(=O)R5, C(=O)OR5, ENTRE OTROS; R2 is aryl, C (= O) R5, C (= O) OR5, among others; R3 ES CICLOALQUILO, ARILO, HETEROARILO, ENTRE OTROS; R3 is cycloalkyl, aryl, heteroaryl, among others; R4 ES HALO, CN, C(=O)OH, ENTRE OTROS; R4 is halo, CN, C (= O) OH, among others; R4b ES H, NH2, CN, NO2, ENTRE OTROS; R4b is H, NH2, CN, NO2, among others; R5 ES ALQUILO, ARILO, CICLOALQUILO, ENTRE OTROS. R5 is alkyl, aryl, cycloalkyl, among others. SON COMPUESTOS PREPERIDOS: 4-(8-(4-(METILSULFONIL)FENILAMINO)-2H-BENZO[b][1,4] OXAZIN-4(3H)-IL)PIPERIDIN-1-CARBOXILATO DE TERT-BUTILO, 4-(8-(4-(METILSULFONIL)FENILAMINO)-3-OXO-2H-BENZO[b][1,4]OXAZIN-4(3H)-IL)PIPERIDIN-1-CARBOXILATO DE TERT-BUTILO, 4-(4-(2-FLUORO-4-(METILSULFONIL)FENILAMINO)-6H-PIRIMIDO[5,4-b][1,4]OXAZIN-8(7H)-IL)PIPERIDIN-1-CARBOXILATO DE TERT-BUTILO, ENTRE OTROS. COMPOUNDS ARE PREPERIDOS: 4- (8- (4- (methylsulfonyl) phenylamino) -2H-benzo [b] [1,4] oxazin-4 (3H) -yl) piperidine-1-carboxylic acid tert-butyl 4- (8- (4- (methylsulfonyl) phenylamino) -3-OXO-2H-benzo [b] [1,4] oxazin-4 (3H) -yl) piperidine-1-carboxylic acid tert-butyl 4- (4 - (2-fluoro-4- (methylsulfonyl) phenylamino) -6H-pyrimido [5,4-b] [1,4] oxazin-8 (7H) -yl) piperidine-1-carboxylic acid tert-butyl LIMITED . TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. ALSO REFERRED TO A PHARMACEUTICAL COMPOSITION. DICHOS COMPUESTOS SON MODULADORES DEL RECEPTOR ACOPLADO A LA PROTEINA G GPR119 Y SON UTILES EN EL TRATAMIENTO DE LA DIABETES, ENFERMEDADES CARDIOVASCULARES, SINDROME METABOLICO, ENTRE OTROS Such compounds are receptor modulators G protein coupled GPR119 and are useful in the treatment of diabetes, CARDIOVASCULAR DISEASE, METABOLIC SYNDROME AMONG OTHERS
PE0007772008A 2007-05-04 2008-04-30 Compounds [6,6] and [6,7] -biciclicos as agonists coupled receptor protein g GPR119 PE02222009A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US91594407P true 2007-05-04 2007-05-04

Publications (1)

Publication Number Publication Date
PE02222009A1 true PE02222009A1 (en) 2009-03-27

Family

ID=39705174

Family Applications (1)

Application Number Title Priority Date Filing Date
PE0007772008A PE02222009A1 (en) 2007-05-04 2008-04-30 Compounds [6,6] and [6,7] -biciclicos as agonists coupled receptor protein g GPR119

Country Status (10)

Country Link
US (4) US7910583B2 (en)
EP (1) EP2144902B1 (en)
JP (1) JP2010526145A (en)
CN (1) CN101668756A (en)
AR (1) AR066437A1 (en)
CL (1) CL2008001271A1 (en)
ES (1) ES2388967T3 (en)
PE (1) PE02222009A1 (en)
TW (1) TW200848055A (en)
WO (1) WO2008137435A1 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg A process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
PE02352011A1 (en) 2006-05-04 2011-04-14 Boehringer Ingelheim Int pharmaceutical combinations comprising metformin and linagliptin
CA2810522A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Polymorphs
CN101801957A (en) * 2007-07-17 2010-08-11 百时美施贵宝公司 pyridone gpr119 g protein-coupled receptor agonists
AR071175A1 (en) 2008-04-03 2010-06-02 Boehringer Ingelheim Int pharmaceutical composition comprising an inhibitor of dipeptidyl peptidase-4 (DPP4) and a companion drug
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
CA2730610A1 (en) * 2008-07-16 2010-01-21 Schering Corporation Bicyclic heterocycle derivatives and their use as gpcr modulators
TW201006821A (en) * 2008-07-16 2010-02-16 Squibb Bristol Myers Co Pyridone and pyridazone analogues as GPR119 modulators
AU2009270971A1 (en) * 2008-07-16 2010-01-21 Schering Corporation Bicyclic Heterocycle Derivatives and use thereof as GPR119 modulators
WO2010009208A1 (en) * 2008-07-16 2010-01-21 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
KR20190016601A (en) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 Treatment for diabetes in patients inappropriate for metformin therapy
WO2010072776A1 (en) 2008-12-23 2010-07-01 Boehringer Ingelheim International Gmbh Salt forms of organic compound
WO2010075273A1 (en) * 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
US20120016119A1 (en) * 2009-01-22 2012-01-19 Yasunori Tsuboi NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND
WO2010088518A2 (en) * 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
JP5657518B2 (en) 2009-02-18 2015-01-21 武田薬品工業株式会社 Condensed heterocyclic compound
EP2414348B1 (en) 2009-04-03 2013-11-20 Merck Sharp & Dohme Corp. Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders
AR077214A1 (en) 2009-06-24 2011-08-10 Neurocrine Biosciences Inc nitrogen heterocycles and pharmaceutical compositions containing them
JP5467151B2 (en) 2009-06-24 2014-04-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング The novel compounds, pharmaceutical compositions and methods relating thereto
KR20170136017A (en) 2009-11-27 2017-12-08 베링거 인겔하임 인터내셔날 게엠베하 Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
US20130109703A1 (en) * 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
US8415367B2 (en) 2010-04-08 2013-04-09 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators
EA201201508A1 (en) 2010-05-05 2013-05-30 Бёрингер Ингельхайм Интернациональ Гмбх Combined therapy
US8729084B2 (en) 2010-05-06 2014-05-20 Bristol-Myers Squibb Company Benzofuranyl analogues as GPR119 modulators
CA2798610A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Bicyclic heteroaryl compounds as gpr119 modulators
TW201202230A (en) * 2010-05-24 2012-01-16 Mitsubishi Tanabe Pharma Corp Novel quinazoline compound
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
EP3124041A1 (en) 2010-06-24 2017-02-01 Boehringer Ingelheim International GmbH Diabetes therapy
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP2013253019A (en) * 2010-09-28 2013-12-19 Kowa Co New piperidine derivative and pharmaceutical containing the same
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
UY33805A (en) * 2010-12-17 2012-07-31 Boehringer Ingelheim Int ? Dihidrobenzofuranilpiperidinilo derivatives, aza-diaza-dihidrobenzofuranilpiperidinilo dihidrobenzofuranilpiperidinilo and pharmaceutical compositions containing them and uses thereof ?.
JP2014501274A (en) 2011-01-03 2014-01-20 ハンミ ファーム. シーオー., エルティーディー. The novel bicyclic compounds for the G protein-coupled receptor modulators
AU2013290100A1 (en) 2012-07-11 2015-01-29 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
CN102617548A (en) * 2011-01-31 2012-08-01 北京赛林泰医药技术有限公司 Bicycloheteroaryl compounds as GPR Receptor stimulant, compositions and application thereof
JP6463631B2 (en) 2011-06-09 2019-02-06 ライゼン・ファーマシューティカルズ・エスアー Novel compounds as modulators of gpr-119
JP5876150B2 (en) 2011-07-15 2016-03-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Substituted quinazoline, use of these these preparation and pharmaceutical compositions
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
EP2850073B1 (en) 2012-05-16 2017-07-19 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449A1 (en) 2014-02-28 2017-01-04 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
CN105218561B (en) * 2014-06-25 2018-10-30 上海艾力斯医药科技有限公司 Ring fused pyrimidine derivatives, their preparation and use
CA3022202A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3826643A (en) * 1967-08-07 1974-07-30 American Cyanamid Co Method of controlling undesirable plant species using 3-nitropyridines
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5488064A (en) * 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5491134A (en) * 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en) * 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5770615A (en) * 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US6566384B1 (en) * 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
TW536540B (en) * 1997-01-30 2003-06-11 Squibb Bristol Myers Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GT199800166A (en) 1997-11-21 2000-04-19 Pfizer Prod Inc Combination of an inhibitor of aldose reductase inhibitor and a glycogen phosphorylase.
JP2002519380A (en) 1998-07-06 2002-07-02 ブリストル−マイヤーズ スクイブ カンパニー Biphenyl sulfonamide compounds as two yuan angiotensin / endothelin-receptor antagonists
WO2000039102A1 (en) 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company THROMBIN OR FACTOR Xa INHIBITORS
CA2413241A1 (en) 2000-06-29 2002-01-10 Bristol-Myers Squibb Pharma Company Thrombin or factor xa inhibitors
EP1770159A1 (en) 2000-12-01 2007-04-04 Astellas Pharma Inc. Process for manufacturing a pharmaceutical composition for treating diabetes
US7482366B2 (en) * 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US7998986B2 (en) * 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
MXPA05007485A (en) 2003-01-14 2006-01-30 Arena Pharm Inc 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia.
EP1606282B1 (en) 2003-02-24 2008-11-12 Arena Pharmaceuticals, Inc. Phenyl- and pyridylpipereidinye-derivatives as modulators of glucose metabolism
SE0301010D0 (en) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
AR045047A1 (en) 2003-07-11 2005-10-12 Arena Pharm Inc Aryl and heteroaryl derivatives as modulators of metabolism trisubstituted and the prophylaxis and treatment of disorders related thereto
CA2532971A1 (en) 2003-07-14 2005-01-27 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20070088163A1 (en) 2003-09-12 2007-04-19 Kemia, Inc. Modulators of calcitonin and amylin activity
EA012071B1 (en) 2004-03-17 2009-08-28 7ТиЭм ФАРМА А/С Y4 receptor selective agonists for therapeutic intervention
WO2005105791A1 (en) * 2004-05-03 2005-11-10 F. Hoffmann-La Roche Ag Indolyl derivatives as liver-x-receptor modulators
EP1756084B1 (en) 2004-06-04 2008-11-26 Arena Pharmaceuticals, Inc. Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
JP5065908B2 (en) * 2004-12-24 2012-11-07 プロシディオン・リミテッドProsidion Limited G-protein coupled receptor agonists
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
WO2007001958A2 (en) * 2005-06-23 2007-01-04 Emory University Stereoselective synthesis of amino acid analogs for tumor imaging
WO2008137436A1 (en) 2007-05-04 2008-11-13 Bristol-Myers Squibb Company [6,5]-bicyclic gpr119 g protein-coupled receptor agonists
CN101801957A (en) 2007-07-17 2010-08-11 百时美施贵宝公司 pyridone gpr119 g protein-coupled receptor agonists

Also Published As

Publication number Publication date
ES2388967T3 (en) 2012-10-22
AR066437A1 (en) 2009-08-19
US7910583B2 (en) 2011-03-22
US20130116237A1 (en) 2013-05-09
EP2144902B1 (en) 2012-05-16
CL2008001271A1 (en) 2008-09-12
JP2010526145A (en) 2010-07-29
US20080293690A1 (en) 2008-11-27
US20120202790A1 (en) 2012-08-09
TW200848055A (en) 2008-12-16
US8314095B2 (en) 2012-11-20
CN101668756A (en) 2010-03-10
US8076322B2 (en) 2011-12-13
WO2008137435A1 (en) 2008-11-13
US20110136783A1 (en) 2011-06-09
EP2144902A1 (en) 2010-01-20
US8513265B2 (en) 2013-08-20

Similar Documents

Publication Publication Date Title
JP5347202B2 (en) Bruton's tyrosine kinase inhibitors
CN102933564B (en) 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
JP6475158B2 (en) Bicyclic heteroaryl derivatives as Mnk1 and mnk2 modifiers, and uses thereof
ES2389116T3 (en) pharmaceutical compositions and methods of use
US8957068B2 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
US20070060595A1 (en) Novel fused heterocyclic compound and use thereof
CR8744A (en) therapeutics
BRPI0416404B1 (en) solid pharmaceutical composition, orally applicable, their process of preparation and use of 5-chloro-N - ({(5S) -2-oxo-3- [4- (3-oxo-4-morpholinyl) phenyl] -1,3-oxazolidin-5-yl} -methyl) -2-thiophenecarboxamide
MX2009007023A (en) Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders.
PE02002003A1 (en) Benzimidazole as inhibitors of MAP kinases
ECSP067013A (en) 2-quinolyl-oxazoles substituted useful as PDE4 inhibitors
PE18162009A1 (en) BACE inhibitors
PE09952011A1 (en) Pyrrolo [3,4-e] pyrimidine as inhibitors of PDE1
KR20140029442A (en) Aryl- or heteroaryl-substituted benzene compounds
PE00412015A1 (en) Functionalized derivatives of amino acids in the n terminal capable of forming microspheres encapsulating drug
PE03742006A1 (en) Kinase inhibitors fused heterocyclic
WO2013066838A1 (en) Compounds and methods
NZ564758A (en) G-protein coupled receptor agonists
TW200800210A (en) Bis-aryl amide compounds and methods of use
PE00082012A1 (en) Phenoxy benzenesulfonamide derivatives
JP2014525438A (en) Heterocyclic compounds and their use
NZ612990A (en) Novel heterocyclic derivatives and their use in the treatment of neurological disorders
TW200811141A (en) Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
PE05852007A1 (en) Sulfonamide derivatives as glucokinase activators
MX2007004882A (en) Xanthine derivatives with hm74a receptor activity.

Legal Events

Date Code Title Description
FC Refusal